A Multicenter Randomized, Double-Blind, Placebo-controlled, Dosing, Safety and Efficacy Study of IMM 124-E (Hyperimmune Bovine Colostrum) for Patients With Severe Alcoholic Hepatitis
Phase of Trial: Phase II
Latest Information Update: 14 Sep 2019
Price : $35 *
At a glance
- Drugs IMM 124E (Primary)
- Indications Alcoholic hepatitis
- Focus Proof of concept; Therapeutic Use
- Acronyms TREAT
- 26 Mar 2019 Status changed from active, no longer recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 30 Jul 2018 Planned End Date changed from 1 Jan 2019 to 22 Dec 2019.